Insulet vs Spyre Therapeutics
Insulet (PODD), health care, and Spyre Therapeutics (SYRE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Insulet is worth $10.1B on the stock market and Spyre Therapeutics $8.9B: Insulet is valued at 13% more. Over the past year Insulet's share price has moved -56.4% and Spyre Therapeutics's +312%.
Key facts
- Insulet market value
- $10.1B
- Spyre Therapeutics market value
- $8.9B
- Insulet P/E
- 23.7
- Insulet revenue
- $2.7BFY to 2025-12-31
- Spyre Therapeutics revenue
- $0FY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Insulet | Spyre Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $10.1Bhigher | $8.9Blower |
| Revenue | $2.7Bhigher | $0lower |
| Earnings | $247.1Mhigher | -$155.2Mlower |
| Employees | 5,400higher | 130lower |
| Total assets | $3.2Bhigher | $777.8Mlower |
| Valuation | ||
| P/E | 23.7 | — |
| P/S | 3.7 | — |
| P/B | 6.4lower | 9.3higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 17.5% | — |
| Balance sheet | ||
| Net assets | $1.5Bhigher | $715.2Mlower |
| Total liabilities | $1.7Bhigher | $62.5Mlower |
| Total debt | $949.2M | — |
| Cash on hand | $716.1Mhigher | $85.7Mlower |
| Price change | ||
| Today | +0.03%higher | -5.60%lower |
| 1 year | -56.4%lower | +312%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Insulet only (1)
- Eric Bannasch9.7%
Spyre Therapeutics only (1)
- Brandon Haley0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns PODD · Who owns SYRE
More on Insulet
Further comparisons
Insulet against its closest peers
Spyre Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Insulet or Spyre Therapeutics?
By market value, Insulet is the larger: $10.1B against $8.9B for Spyre Therapeutics. By revenue in its latest fiscal year, Insulet is the larger: $2.7B against $0 for Spyre Therapeutics.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Insulet and Spyre Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Insulet and 1 holds Spyre Therapeutics.
Cite this page
Funkfolio, “Insulet vs Spyre Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/podd-vs-syre
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.